Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
May 24, 2013 – The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International (CDI) exclusive license rights to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. These cells are capable of further differentiation into the multiple cell …
Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria
May 17, 2013 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria (AIP). The …
Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh To Collaborate On Clinical Studies For Mucopolysaccharidoses
May 15, 2013 – The Icahn School of Medicine at Mount Sinai has signed an agreement with bene pharmaChem GmbH to collaborate to conduct clinical studies of pentosan polysulfate (PPS) in patients with mucopolysaccharidoses (MPS). The company, based in Germany, is the sole producer of pharmaceutical …
Mount Sinai Invents Gene Signature to Identify Individuals with Cirrhosis at High-Risk for Liver Cancer
April 17, 2013 – Researchers at the Icahn School of Medicine at Mount Sinai have developed the first-ever gene test that could be used to identify patients with cirrhosis who are at highest risk of developing the most common type of liver cancer, …
The Icahn School of Medicine at Mount Sinai Partners with Genisphere to Develop Rapid, High-Throughput Allergy Test
January 31, 2013 – The Icahn School of Medicine at Mount Sinai and Genisphere have agreed to jointly develop a new allergy test that will quickly and effectively characterize patients’ food allergies. The peptide-bead-based test will be high-throughput, semi-automatic and accurate, surpassing …
Anti-Cancer Activity Drug IRX4204 Shows Promise as a Potential Disease-Modifying Agent for Alzheimer’s Disease
September 13, 2012 – New research presented today at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco, California demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer’s disease. The presentation entitled “Investigation …
Mount Sinai Researchers Develop New Computational Method to Find Novel Connections from Gene to Gene, Drug to Drug and Between Scientists
July 23, 2012 – Researchers from Mount Sinai School of Medicine have developed a new computational method that will help organize scientific data, making it easier for scientists to identify and prioritize genes, drug targets, and connections between drugs. By mining large …
Mount Sinai School of Medicine and PATH Agree To Collaborate on Novel Influenza Vaccine Research
July 16, 2012 – Mount Sinai School of Medicine (MSSM) and PATH have reached an agreement to partner on new vaccine research aimed at eliciting broadly-protective immunity against influenza viruses. The collaboration seeks to develop promising influenza vaccines that can be made available …
Mount Sinai Researchers Develop A Multi-Target Approach To Treating Tumors
June 7, 2012 – Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound …
Partnership Investment Fund Awards $1M to Support Four Promising Biomedical Products
June 4, 2012 – The Partnership for New York City (PFNYC) today announced that four local scientists have been awarded a total of $1 million to fund the final stages of research on new biomedical products that will be developed in the …